Printer Friendly

Therapeutic applications of RNAi; methods and protocols.

9781603272940

Therapeutic applications of RNAi; methods and protocols.

Ed. by John F. Reidhaar-Olson.

Humana Press Inc.

2009

148 pages

$99.50

Hardcover

Methods in molecular biology, 555

QP623

RNA interference, RNAi, has quickly become a standard tool in the drug discovery process because it can prevent the expression of pretty much any gene in the mammalian genome. Specialist researchers here describe laboratory methods for investigating possible therapeutic applications of the process and its products. Among their topics are targeted gene silencing in solid tumors with electrically mediated siRNA delivery, silencing virus replication, RNAi in the malaria vector Anopheles gambiae, lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi, studying autoimmunity by in-vitro RNA interference, and alternative splicing as a therapeutic target for human diseases.

([c]2009 Book News, Inc., Portland, OR)

COPYRIGHT 2009 Book News, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SciTech Book News
Article Type:Book review
Date:Dec 1, 2009
Words:133
Previous Article:Crevasse roulette; the first trans-antarctic crossing 1957-58.
Next Article:Atomic, molecular, and optical physics; new research.
Topics:


Related Articles
Alnylam licenses intellectual property in RNA interference.
Alnylam and Cenix enter into RNAi research service agreement.
Mirus Bio awarded broad RNAi patent using hydrodynamic intravascular injection.
Intradigm Strengthens RNA Interference (RNAi) Position with MIT License.
Intradigm Announces Allowance of Key RNA Interference Patent Patent Covers Small Interfering RNA Structural Features Tied to Increased Efficacy and...
RNA interference research progress.
Gene knockout protocols, 2d ed.
RXI ACQUIRES OWNERSHIP OF PREVIOUSLY LICENSED RNAI DELIVERY.
Intradigm announces issuance of RNA interference (RNAi) patent covering potent siRNA sequence.
Isis receives notice of allowance that expands the scope of key RNA therapeutic patents for single-stranded RNAi technology.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters